Neurodegenerative disorders and nanoformulated drug development.

Department of Pharmacology & Experimental Neuroscience, Center for Neurovirology & Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.
Nanomedicine (Impact Factor: 5.26). 08/2009; 4(5):541-55. DOI: 10.2217/nnm.09.37
Source: PubMed

ABSTRACT Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Major central nervous system disorders represent a significant and worldwide public health problem. In fact, the therapeutic success of many pharmaceuticals developed to treat central nervous system diseases is still moderate, since the blood-brain barrier (BBB) limits the access of systemically administered compounds to the brain. Therefore, they require the application of a large total dose of a drug, and cause numerous toxic effects. The development of nanotechnological systems are useful tools to deliver therapeutics and/or diagnostic probes to the brain due to nanocarriers having the potential to improve the therapeutic effect of drugs and to reduce their side effects. This review provides a brief overview of the variety of carriers employed for central nervous system drug and diagnostic probes delivery. Further, this paper focuses on the novel nanocarriers developed to enhance brain delivery across the blood-brain barrier. Special attention is paid to liposomes, micelles, polymeric and lipid-based nanoparticles, dendrimers and carbon nanotubes. The recent developments in nanocarrier implementation through size/charge optimization and surface modifications (PEGylation, targeting delivery, and coating with surfactants) have been discussed. And a detailed description of the nanoscaled pharmaceutical delivery devices employed for the treatment of central nervous system disorders have also been defined. The aim of the review is to evaluate the nanotechnology-based drug delivery strategies to treat different central nervous system disorders.
    Journal of Nanoscience and Nanotechnology 01/2014; 14(1):766-79. DOI:10.1166/jnn.2014.9119 · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study we present an overview of the recent results of a novel approach to antioxidant and anticancer therapies, consisting in the administration of intrinsically active nano-structured particles. Their particulate (as opposed to molecular) nature allows designing multifunctional platforms via the binding of molecular determinants, including targeting molecules and chemotherapy drugs, thereby facilitating their localization at the desired site. The intrinsic activity of nanomaterials with pharmacological potential include peculiar trans-excitation reactions that render them able to transform radiofrequency, UV, visible or infrared radiations into cytocidal reactive oxygen species or heat, thereby inducing local cytotoxity in selected areas. The use of such devices has been shown to improve the efficacy of antitumor chemo- and radio-therapies, increasing the selectivity of the cytocidal effects, and reducing systemic side effects. In addition, catalytic nanomaterials such as cerium oxide nanoparticles can perform energy-free antioxidant cycles that scavenge the most noxious reactive oxygen species via SOD- and catalase-mimetic activities. A vast body of in vivo and in vitro studies has demonstrated that they reduce the damage induced by environmental stress and ameliorate an impressive series of clinically relevant oxidation-related pathologies. Similar effects are reported for carbon-based materials such as fullerenes. Overall, great improvements are expected by this novel approach. However, caution must be posed due to the poor knowledge of possible adverse body reactions against these novel devices, thoroughly analyzing the biocompatibility of these nanomaterials, especially concerning the biokinetics and the problems potentially caused by long term retention of non-biodegradable inorganic nanomaterials.
    Biochemical Pharmacology 08/2014; 92(1). DOI:10.1016/j.bcp.2014.08.015 · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article has been retracted: please see Elsevier Policy on Article Withdrawal ( This article has been retracted at the request of the Editor-in-Chief. Due to highly unethical practices, which include serial self plagiarism, data manipulation and falsification of results found across multiple papers in Acta Biomaterialia. One of the conditions of submission of a paper for publication is that authors declare explicitly that their work is original and has not appeared in a publication elsewhere. Re-use of any data should be appropriately cited. As such this article represents a severe abuse of the scientific publishing system. The scientific community takes a very strong view on this matter and apologies are offered to readers of the journal that this was not detected during the submission process.
    Acta biomaterialia 06/2013; 9(6):7074. DOI:10.1016/j.actbio.2012.03.048 · 5.68 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014